127 related articles for article (PubMed ID: 23460270)
1. Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase.
Jain P; Sargent RL; Konoplev SN; Benjamini O; Kantarjian H; Kadia T
Am J Hematol; 2013 May; 88(5):433-4. PubMed ID: 23460270
[No Abstract] [Full Text] [Related]
2. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
[TBL] [Abstract][Full Text] [Related]
3. The t(9;14)(p13;q32) is a recurrent but rare abnormality in splenic marginal zone lymphoma.
Kelly RJ; O'connor SJ; Barrans SL; Johnson RJ; Owen RG
Leuk Lymphoma; 2007 Aug; 48(8):1636-7. PubMed ID: 17701598
[No Abstract] [Full Text] [Related]
4. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
Arcaini L; Rossi D; Lucioni M; Nicola M; Bruscaggin A; Fiaccadori V; Riboni R; Ramponi A; Ferretti VV; Cresta S; Casaluci GM; Bonfichi M; Gotti M; Merli M; Maffi A; Arra M; Varettoni M; Rattotti S; Morello L; Guerrera ML; Sciarra R; Gaidano G; Cazzola M; Paulli M
Haematologica; 2015 Feb; 100(2):246-52. PubMed ID: 25381127
[TBL] [Abstract][Full Text] [Related]
5. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.
Zaja F; Salvi F; Rossi M; Sabattini E; Evangelista A; Ciccone G; Angelucci E; Gaidano G; Zanni M; Ladetto M; Chiappella A; Vitolo U; Zinzani PL; Califano C; Tucci A; Patti C; Pileri SA; Lenti V; Piccaluga PP; Cavallo F; Volpetti S; Perali G; Assouline S; Mann KK; Morin R; Alcaide M; Bushell K; Fanin R; Levis A
Leuk Lymphoma; 2018 Dec; 59(12):2904-2910. PubMed ID: 29616865
[TBL] [Abstract][Full Text] [Related]
6. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.
Ollila TA; Kurt H; Waroich J; Vatkevich J; Sturtevant A; Patel NR; Dubielecka PM; Treaba DO; Olszewski AJ
Blood; 2021 Feb; 137(8):1120-1124. PubMed ID: 32877514
[No Abstract] [Full Text] [Related]
7. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
[TBL] [Abstract][Full Text] [Related]
8. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
[TBL] [Abstract][Full Text] [Related]
9. An Epstein-Barr virus-positive diffuse large B-cell lymphoma presenting as multi-organ failure: a catastrophic lymphomatosis with fulminant visceral organ dissemination resulting in a precipitous death in a 59-year-old female with no identifiable etiology for immunodeficiency.
Wang E; Papavassiliou P; Wei Q; Wickham MQ; Cichon L; Proia AD
Pathol Res Pract; 2014 Jan; 210(1):62-6. PubMed ID: 24120731
[TBL] [Abstract][Full Text] [Related]
10. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Tilly H; Vitolo U; Walewski J; da Silva MG; Shpilberg O; André M; Pfreundschuh M; Dreyling M;
Ann Oncol; 2012 Oct; 23 Suppl 7():vii78-82. PubMed ID: 22997459
[No Abstract] [Full Text] [Related]
11. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Phillips T; Barr PM; Park SI; Kolibaba K; Caimi PF; Chhabra S; Kingsley EC; Boyd T; Chen R; Carret AS; Gartner EM; Li H; Yu C; Smith DC
Invest New Drugs; 2019 Apr; 37(2):297-306. PubMed ID: 30132271
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy.
Yi JH; Kim SJ; Ko YH; Kim WS
Leuk Lymphoma; 2011 Feb; 52(2):317-20. PubMed ID: 21067447
[No Abstract] [Full Text] [Related]
13. Haemodynamic instability secondary to cardiac involvement by lymphoma.
Lal KS; Tariq RZ; Okwuosa T
BMJ Case Rep; 2016 Jun; 2016():. PubMed ID: 27307428
[TBL] [Abstract][Full Text] [Related]
14. Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
Miljkovic MD; Roschewski M; Dunleavy K; Wilson WH
Leuk Lymphoma; 2019 Dec; 60(13):3320-3323. PubMed ID: 31204529
[No Abstract] [Full Text] [Related]
15. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.
Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS; Lu SC
Ann Hematol; 2012 Nov; 91(11):1741-5. PubMed ID: 22729139
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
[No Abstract] [Full Text] [Related]
17. Late-delayed cerebral involvement in systemic non-Hodgkin lymphoma: a second primary tumor or a tardy recurrence?
Lossos A; Ashhab Y; Sverdlin E; Amir G; Ben-Yehuda D; Siegal T
Cancer; 2004 Oct; 101(8):1843-9. PubMed ID: 15372481
[TBL] [Abstract][Full Text] [Related]
18. Transformed cell lymphoma.
J Tenn Med Assoc; 1977 May; 70(5):330-2, 342. PubMed ID: 325298
[No Abstract] [Full Text] [Related]
19. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
20. Diffuse large B-cell lymphoma recurrence presenting as multiple, progressive cranial neuropathies.
Goron AR; Devlin S; Schwartz S
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31326905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
